




Investor Fact Sheet

Financial key figures 2019/20


in thousand CHF

	01 April 2019– 31 March 2020	in %	01 April 2018– 31 March 2019	in %	thereof discontinued operation	thereof continued operations
Sales of goods and services group	393866	100.0%	453765	100.0%	100944	352821
Ypsomed Diabetes Care	187309	47.6%	280425	61.8%	100944	179481
Ypsomed Delivery Systems	192032	48.8%	155730	34.3%		155730
Others	14526	3.7%	17610	3.9%		17610
Operating profit group	9289	2.4%	73344	16.2%	61896	11448
Financial income	4417	1.1%	3197	0.7%		
Financial expenses	-6250	-1.6%	-6660	-1.5%		
Income taxes	3996	1.0%	-9744	-2.1%		
Net profit	11452	2.9%	60136	13.3%		
Earnings per share in CHF	0.91		4.77			
Operating profit	9289		73344			
Depreciation and impairment of fixed assets	30365		25747			
Amortisation and impairment of intangible assets	22434		19141			
EBITDA (Operating profit before depreciation and amortisation)	62088	15.8%	118232	26.1%		

Development of turnover at group level



Development of EBIT at group level



Further information: Information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group can be found in the Annual Report 2019/20 and at www.ypsomed.ch.



Ypsomed Diabetes Care

With its mylife™ Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed's subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).

Diabetes: A global disease with pandemic growth predicted in the coming 20 years. Currently diabetes is growing at approximately 9% p. a. Due to that fact Ypsomed is expanding its network of subsidiaries consequently with its outstanding product portfolio.

mylife™ product portfolio (selection)



Ypsomed Delivery Systems

Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world's largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.

Trends for future drugs: Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.

YDS product portfolio (selection)



Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.